DTC Laissez-faire: A Bankrupt Policy
Some experts are worried that the recent COX-2 FDA advisory committee vote to ban direct-to-consumer (DTC) advertising of COX-2 drugs is a harbinger of stricter DTC regulation by the FDA across...
FDA Advisory Panels: Elephants in the Room
The New York Times recently reported that "Ten of the 32 government drug advisers who last week endorsed continued marketing of the huge-selling pain pills Celebrex, Bextra and Vioxx have consulted...
Febraury Issue of Pharma Marketing News Is Here
Pharma Marketing News Subscribe Today and get it FREE!CURRENT ISSUE: Vol. 4, No. 2: February 2005Links to summaries of individual articles below. ArticlesYou May Walk Like a Duck and Quack Like...
Vioxx Redux
Just when you thought it was safe to go back into the water, Merck suggests that it may put Vioxx back on the market, according to an article in today's Wall...
Drug Safety: A Matter of Trust!
Those Canadians are at it again! Quick they are at being contrary to the U.S. This even extends to drug safety issues.As reported in the WSJ on 9 February 2005, the...
Time for Pharma to Revamp Its Physician Marketing Strategy
Should pharma companies revamp their physician marketing strategies? Some idea of pharma's thinking on this topic is revealed in the emerging story of Pfizer's plans for its own sales force. ...
Pharma Sales Force Bloat and the Mythical Man-Month
A myth long believed at pharma companies --as well as at other companies -- is that by by hiring more salespeople you can proportionately increase sales without limit. Want to double...
Pfizer to Slash 30% of its Sales & Marketing Staff
Pfizer Inc. may slash its 38,000-member sales and marketing staff by as much as 30%, or 11,400 employees.
Pfizer Inc., the world's biggest drugmaker, may cut as much as 30 percent of...
It’s the land of success!
Big Pharma had a plan.
It designed a trial for a COX-2 drug and it ran.
Yet it wasn’t enough to get pain low.
What's this?
We’re still here in the land of no? ...
Buzz is NOT regulated by FDA
It seems that Cialis will be back at the Super Bowl with a 60-second commercial that may cost as much as $4.8 million (see "Impotence drug returns to Super Bowl ...
